De Bacquer, Dirk http://orcid.org/0000-0002-3202-7238
,
De Smedt, Delphine
Kotseva, Kornelia
Jennings, Catriona
Wood, David
Rydén, Lars
Gyberg, Viveca
Shahim, Bahira
Amouyel, Philippe
Bruthans, Jan
Castro Conde, Almudena
Cífková, Renata
Deckers, Jaap W.
De Sutter, Johan
Dilic, Mirza
Dolzhenko, Maryna
Erglis, Andrejs
Fras, Zlatko
Gaita, Dan
Gotcheva, Nina
Goudevenos, John
Heuschmann, Peter
Laucevicius, Aleksandras
Lehto, Seppo
Lovic, Dragan
Miličić, Davor
Moore, David
Nicolaides, Evagoras
Oganov, Raphael
Pajak, Andrzej
Pogosova, Nana
Reiner, Zeljko
Stagmo, Martin
Störk, Stefan
Tokgözoğlu, Lale
Vulic, Dusko
Wagner, Martin
De Backer, Guy
Article History
Received: 18 April 2018
Accepted: 10 October 2018
First Online: 23 October 2018
Compliance with ethical standards
:
: (1) KK, DDB, CJ, VG, LR and DW had grant support from the European Society of Cardiology for the submitted work; VG was supported by a Grant from the Swedish Heart and Lung Foundation; AP was supported by a grant from the Polish National Science Centre (Contract DEC-2011/03/B/N27/06101); JB was supported by the Grant No. NT 13186 by the Internal Grant Agency, Ministry of Health, Czech Republic; DM had grants from Servier, MSD, Sanofi-Aventis, Menarini; PA had grants from AstraZeneca; SS had grants from German Ministry of Research and Education via the Comprehensive Heart Failure Centre, University of Würzburg; (2) DW, LR, KK, VG, PA, MD, MS, PH, RC, AE, DG, ZR, LT had the following financial activities outside the submitted work in the previous 3 years: DW, honoraria for invited lectures or advisory boards: AstraZeneca, Merck Sharp and Dohme, Kowa Pharmaceuticals, Menarini, Zentiva; consultancy: Merck Sharp and Dohme; LR, Grants from Swedish Heart Lung Foundation, Swedish Diabetes Association, Roche AG, Bayer AG and Karolinska Institute Funds, personal fees from Roche, SanofiAventis, and Bayer AG; KK, travel Grants from Roche and Boehringer Ingelheim; VG, lecture fees from MSD Sweden; PA had grants and personal fees from Fondation Plan Alzheimer, Servier, Alzprotect, Total, Hoffman Roche, Daichi Sankyo, Genoscreen; MD, grants from Universal Agency ‘Profarma’; MS was temporarily employed by MSD Sweden AB as Associate Director, medical affairs, during part of the study period; PH receives/received in the recent years research support from the German Ministry of Research and Education (Centre for Stroke Research Berlin; Comprehensive Heart Failure Centre Würzburg), the European Union (European Implementation Score Collaboration), the German Stroke Foundation, the Charité—Universitätsmedizin Berlin, the Berlin Chamber of Physicians, and the University Hospital of Würzburg; RC had grants from Krka, Novo Mesto, Slovenia, personal fees from Servier International, Medtronic, Medtronic Czechia, Abbott Products Operations AG, MSD Czech Republic, TEVA Pharmaceuticals Czech Republic; ZR had personal fees from Sanofi, AstraZeneca, Abbott, and Aegirion; AE had grants and personal fees from Abbott Vascular, Boston Scientific, Biosensors, Biotronik, Cordis J&J, Medtronik; DG had personal fees from AstraZaneca, Abbott, Novartis and Sanofi; LT had lecture honoraria from Abbott, MSD, Bayer, AstraZaneca, Boehringer Ingelheim, Pfizer, Sanofi, Servier, Kowa and Actelion, and (3) ACC, JWD, JDS, MD, ZF, DL, NG, AL, DL, EN, RO, NP, DV have no financial interests that are relevant to the submitted work.